anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
Kırıkkale University Faculty of Medicine Physical Therapy will be hospitalized in the USA clinic and volunteers will be involved in stroke rehabilitation. The patients who meet the inclusion criteria and who are excluded from the exclusion criteria will be randomized according to the order of arrival and will be divided into two groups as the education group and the control group. Patients will be taken to the control and study group respectively in order of arrival. If the next patient falls outside the inclusion criteria of the study, randomization will be applied to the next patient. Patients in the control group will be given routine conventional physiotherapy in 4-week and 60-minute sessions. The training group will be given routine conventional physiotherapy in 4-week and 45-minute sessions.In addition, three sessions a week will be applied to the soles of the feet for 15 minutes with a 15-100 Hz vibration device on both sides of the soles of the feet before conventional physical therapy. Individuals before; age, gender, marital status, nutritional characteristics, habits, smoking and alcohol, auxiliary devices, background information, family history, educational status, social security, previous or current occupation, frequency of fall, cause of fall and drugs used will be questioned. Static and dynamic equilibrium parameters will be evaluated at the beginning of the study and at the end of the 4th week.
The invention discloses a mild sterilization type alcohol-containing washing-free disinfection gel and a preparation method thereof. The mild sterilization type alcohol-containing no-clean disinfection gel comprises ethanol, an efficacy agent, a thickening agent, a humectant, a pH regulator and deionized water. The mild sterilization type alcohol-containing no-clean disinfection gel prepared by the invention has fresh skin feel on no-clean and effective bacteriostasis on sterilization. The product mildness is improved by reducing the alcohol consumption of the product, the sterilizing property of the product is ensured by compounding the efficacy agent VLC with the ethanol, and the good refreshing property is provided by the selection of the gel matrix and the addition of the humectant. The preparation process is simple, the price is low, and the preparation process has the advantage of larger market price. Is suitable for the fields of medical institutions, public transportation, stadiums, daily hand cleaning and disinfection, and the like.
INTRODUCTION: Symptomatic intracranial hypertension (IH) due to venous outflow obstruction secondary to dural venous sinus (DVS) tumoral invasion affects up to 3% of intracranial meningioma patients. The literature regarding endovascular therapies of such patients is limited to a few case reports and a recent single-centre case series.
PURPOSE: We describe our single-centre experience of endovascular therapy in patients with clinically symptomatic IH secondary to DVS meningioma invasion.
METHODS: We performed a retrospective review of clinical and radiological data of all patients with refractory IH and meningiomas invading the DVS who were referred for possible DVS venoplasty and stenting. Seven endovascular procedures in six female patients were done. Presumed secondarily induced lateral transverse sinus stenosis was also stented in four patients as part of the primary intervention.
RESULTS: All patients experienced complete symptomatic resolution at 6-month follow-up. Five patients had no symptom recurrence over a mean follow-up period of 3.5 years. One patient with multiple meningiomas developed recurrent IH 2 years following stenting secondary to in-stent tumour re-invasion. This was re-stented with consequent 6 months post-retreatment symptomatic relief at the time of writing. No procedure-related complications occurred.
CONCLUSION: In the setting of DVS stenosis secondary to meningioma invasion, endovascular therapy is a safe and successful therapeutic option with promising mid-term results. The procedure should be considered in cases where complete surgical tumour resection is unlikely or carries a significant risk. If present, secondarily induced stenoses at the lateral ends of the transverse sinuses should also be considered for treatment.
5wPatients with end stage kidney disease (ESKD) who receive in-center hemodialysis are disproportionately vulnerable to extreme weather events, including hurricanes and heat waves, that may disrupt access to healthcare providers, and life-sustaining treatments. This current era of climate-driven compounding disasters is progressively elevating the level of threat to the health and well-being of patients with ESKD. This analysis brings together multi-disciplinary expertise to explore the contours of this increasingly complex risk landscape. Despite the challenges, important advances have been made for safeguarding this medically high-risk patient population. Hemodialysis services providers have devised innovative systems for preparing their patients and sustaining, or rapidly reestablishing, hemodialysis services in the aftermath of a disaster, and maintaining open lines of communication with their caseloads of ESKD patients throughout all phases of the event. A description of lessons learned along the path towards improved patient support in disasters, is provided. The article concludes with a detailed case example, describing dialysis providers' effective response throughout Hurricane Ian's passage across the State of Florida in 2022. Based on lessons learned, this analysis outlines strategies for protecting patients with ESKD that may be adapted for future climate-potentiated disaster scenarios.
The patient was a 35-year-old man who saw his first doctor with the chief complaint of painful urination. A contrast- enhanced CT scan of the abdomen revealed a diagnosis of abscess-forming appendicitis with inflammatory spread to the bladder, and conservative treatment was decided. Since antibiotic treatment failed to reduce the size of the abscess, he underwent surgery. The bladder wall was highly inflamed, only appendectomy was performed. Pathology revealed appendiceal mucinous carcinoma invading the bladder, so he was referred to our department. Because a total cystectomy was required for curative resection and there was concern about seeding associated with the initial surgery, he was judged to be unresectable, and received chemotherapy. After 6 courses of CAPOX+bevacizumab therapy, he was able to have a bladder- sparing curative resection because of the absence of distant metastasis and shrinkage of the tumor. He remains stable without recurrence 6 months after surgery. We herein report, with some discussion of the literature, this case of bladder-invading appendiceal mucinous carcinoma arising from abscess-forming appendicitis, for which a curative resection was possible after chemotherapy.
Disclosed is a reverse genetics system for producing a genotype-matched live attenuated vaccine against a genotype VII Newcastle disease virus (NDV). The reverse genetic system comprises a full-length antigenomic clone, helper plasmids, mammalian cells, and SPF eggs. The full-length antigenomic clone comprises an antigenome of NDV IBS025/13. The antigenome of NDV IBS025/13 is modified, synthesized and cloned into a low copy number pOLTV5-phix transcription vector. The helper plasmids vector the antigenome of NDV IBS025/13. The helper plasmids are expression constructs carrying an NP gene, a P gene and an L gene derived from the antigenome of NDV IBS025/13. Further, the helper plasmids are expressed in mammalian cells. The mammalian cells are BHK-21 cells genetically engineered to express a T7 RNA polymerase. The antigenome of NDV IBS025/13 is rescued following the expression of the T7 RNA polymerase with the full-length antigenomic clone and the helper plasmids. The SPF eggs amplify the rescued antigenome of NDV IBS025/13 from the mammalian cells.   The most illustrative drawing: FIG. 1
Placebo tablets will be used in conjunction to Ketamine infusions for the treatment of major depression disorder or bipolar disorder type I or II. Before the first ketamine infusion, subjects will be randomized to 2 weeks of placebo treatment. All subjects will receive three IV ketamine infusions (0.5 mg/kg, over 100 min.) over 7 days. Those who achieve positive response (\>50% decrease in MADRS total score from baseline) will be given 4 additional once-weekly ketamine infusions (same dose and infusion rate) and placebo treatment.
The invention discloses a biomimetic amphiphilic graft copolymer with a cell membrane structure. The main chain of the copolymer is chitosan, and the side chains are hydrophilic choline phosphate and hydrophobic aliphatic acid. The prepared amphiphilic graft copolymer has the biomimetic characteristics of cell membrane in structure; the choline phosphate molecules mimic the head parts of phospholipid molecules in cell membrane, the sugar units of the chitosan mimic the head parts of the glycolipid molecules in the cell membrane, and the hydrophobic aliphatic acid mimic the hydrophobic carbon chains of the phospholipid molecules and the glycolipid molecules. The copolymer has very good biological compatibility and hydrophilicity. When the copolymer is taken as the nano drug carrier, the copolymer can resist the non-specific adhesion of proteins, and can be easily swollen by the focal cells. Moreover, the graft copolymer can be evenly and stably dispersed in a solution with a high salinity and wide pH range. The invention further provides a preparation method of the copolymer at the same time. The preparation method has the advantages of simple operation, low cost, mild reaction conditions, and high yield.
<P>PROBLEM TO BE SOLVED: To provide a tool useful for developing a medicine that regulates immunoreaction through action or activity of Th1 cell-specific Txk or useful for diagnosing or treating immunological diseases and an application thereof.  <P>SOLUTION: The protein complex comprises at least two kinds of proteins selected from the group consisting of Txk, EF-1α and PARP-1. The index agent for regulation of immunoreaction comprises the proteins. The screening method for identifying a substance for regulating Th1/Th2 immunoreaction comprises supplying the index agent under a condition that the Txk, EF-1α and PARF-1 form a protein complex and using any process of (1) a process for assaying the degree of formation of the complex in the presence of a test subject, (2) a process of assaying the degree of phosphorylation of the complex in the presence of a test subject and (3) a process for assaying ability of combination of the complex with Txk RE DNA in the presence of a test subject. The diagnostic detects the complex. The medicine composition treats diseases through regulation of Th1/Th2 immunoreaction. The active ingredients of the medicine composition are used for producing the medicine.  <P>COPYRIGHT: (C)2006,JPO&NCIPI
Peripheral artery disease (PAD) affects more than 8 million Americans. Although exercise, smoking cessation, anti-platelet therapy, cilostazol, statins and revascularization are used to treat PAD, men and women with PAD have significantly greater functional impairment and fasterfunctional decline than those without PAD. Stem and progenitor cell (PC) therapy that promotes neoangiogenesis is an emerging treatment modality in PAD. Progenitor cells, particularly those of endothelial origin, are involved in vascular repair and regeneration. They originate primarily but not exclusively from the bone marrow, differentiate into endothelial and other vascular cells, and contribute to neovascularization during tissue repair by direct and paracrine mechanisms. Endogenous, pharmacologically-stimulated, and exogenous PCs contribute to re-endothelialization and neovascularization. Granulocyte colony stimulating factor (G-CSF) and granulocyte-macrophage colony stimulating factor (GM-CSF) stimulate mobilization of hematopoietic and other PCs from the bone marrow.In the murine hind limb ischemia model, GM-CSF administered by injection or by plasmid transfer augments circulating levels of PCs, increases capillary density, and promotes arteriogenesis.GM-CSF also augments neo-endothelialization of denuded arteries, promotes proliferation, differentiation and survival of hematopoietic cells, monocytes and macrophages.
This study explores spatial perception of depth by employing a novel proof of concept sensory substitution algorithm. The algorithm taps into existing cognitive scaffolds such as language and cross modal correspondences by naming objects in the scene while representing their elevation and depth by manipulation of the auditory properties for each axis. While the representation of verticality utilized a previously tested correspondence with pitch, the representation of depth employed an ecologically inspired manipulation, based on the loss of gain and filtration of higher frequency sounds over distance. The study, involving 40 participants, seven of which were blind (5) or visually impaired (2), investigates the intrinsicness of an ecologically inspired mapping of auditory cues for depth by comparing it to an interchanged condition where the mappings of the two axes are swapped. All participants successfully learned to use the algorithm following a very brief period of training, with the blind and visually impaired participants showing similar levels of success for learning to use the algorithm as did their sighted counterparts. A significant difference was found at baseline between the two conditions, indicating the intuitiveness of the original ecologically inspired mapping. Despite this, participants were able to achieve similar success rates following the training in both conditions. The findings indicate that both intrinsic and learned cues come into play with respect to depth perception. Moreover, they suggest that by employing perceptual learning, novel sensory mappings can be trained in adulthood. Regarding the blind and visually impaired, the results also support the convergence view, which claims that with training, their spatial abilities can converge with those of the sighted. Finally, we discuss how the algorithm can open new avenues for accessibility technologies, virtual reality, and other practical applications.
Viruses capable of causing persistent infection have developed sophisticated mechanisms for evading host immunity, and understanding these processes can reveal novel features of the host immune system. One such virus, human pegivirus (HPgV), infects ~15% of the global human population, but little is known about its biology beyond the fact that it does not cause overt disease. We passaged a pegivirus isolate of feral brown rats (RPgV) in immunodeficient laboratory mice to develop a mouse-adapted virus (maPgV) that established persistent high-titer infection in a majority of wild-type laboratory mice. maRPgV viremia was detected in the blood of mice for >300 days without apparent disease, closely recapitulating the hallmarks of HPgV infection in humans. We found a pro-viral role for type-I interferon in chronic infection; a lack of PD-1-mediated tolerance to PgV infection; and multiple mechanisms by which PgV immunity can be achieved by an immunocompetent host. These data indicate that the PgV immune evasion strategy has aspects that are both common and unique among persistent viral infections. The creation of maPgV represents the first PgV infection model in wild-type mice, thus opening the entire toolkit of the mouse host to enable further investigation of this persistent RNA virus infections.
The present invention relates to a pulp devitalizer of an oral cavity material and a preparation method thereof. The pulp devitalizer is composed of a pulp devitalization medicine, a local anaesthesia medicine, excipient, a penetrating agent, a colorant and a forming agent, wherein both the devitalization medicine and the local anaesthesia analgesic medicine do not adopt the national special control poisons and anaesthetic: cocaine and arsenic trioxide. Thus, the raw materials of the medicine are sufficient, and the market demand can be satisfied. The formula medicines in the present invention have the advantages of high stability, convenient storage, strong penetrating power, good diffusibility, apparent and quick odgnolysis, and small toxic side effect. No one allergic reaction occurs in the clinical observation for four years, the teeth are not polluted, and the cost is only one-one hundred thirty-fourth of the prior art. The present invention can be widely suitable for odontopathy patients of adults and children.
Background and purpose: Acute kidney injury (AKI) is a common serious complication in sepsis patients with a high mortality rate. This study aimed to develop and validate a predictive model for sepsis associated acute kidney injury (SA-AKI). Methods: In our study, we retrospectively constructed a development cohort comprising 733 septic patients admitted to eight Grade-A tertiary hospitals in Shanghai from January 2021 to October 2022. Additionally, we established an external validation cohort consisting of 336 septic patients admitted to our hospital from January 2017 to December 2019. Risk predictors were selected by LASSO regression, and a corresponding nomogram was constructed. We evaluated the model's discrimination, precision and clinical benefit through receiver operating characteristic (ROC) curves, calibration plots, decision curve analysis (DCA) and clinical impact curves (CIC) in both internal and external validation. Results: AKI incidence was 53.2% in the development cohort and 48.2% in the external validation cohort. The model included five independent indicators: chronic kidney disease stages 1 to 3, blood urea nitrogen, procalcitonin, D-dimer and creatine kinase isoenzyme. The AUC of the model in the development and validation cohorts was 0.914 (95% CI, 0.894-0.934) and 0.923 (95% CI, 0.895-0.952), respectively. The calibration plot, DCA, and CIC demonstrated the model's favorable clinical applicability. Conclusion: We developed and validated a robust nomogram model, which might identify patients at risk of SA-AKI and promising for clinical applications.
The dose of KETEK tablets is 800 mg (2 tablets of 400 mg) taken orally once every 24 hours, for 7–10 days. KETEK tablets can be administered with or without food.

KETEK may be administered without dosage adjustment in the presence of hepatic impairment.

In the presence of severe renal impairment (CLCR < 30 mL/min), including patients who need dialysis, the dose should be reduced to KETEK 600 mg once daily. In patients undergoing hemodialysis, KETEK should be given after the dialysis session on dialysis days. (See CLINICAL PHARMACOLOGY, Renal insufficiency.)

In the presence of severe renal impairment (CLCR < 30 mL/min), with coexisting hepatic impairment, the dose should be reduced to KETEK 400 mg once daily. (See CLINICAL PHARMACOLOGY, Multiple insufficiency.)
Stress-induced antinociception (SIA) is due to the activation of several neural pathways and neurotransmitters that often suppress pain perception. Studies have shown that the orexin neuropeptide system is essential in pain modulation. Therefore, this study aimed to investigate the role of orexinergic receptors in the hippocampal CA1 region in modulating SIA response during the formalin test as an animal model of inflammatory pain. The orexin-1 receptor (OX1r) antagonist, SB334867, at 1, 3, 10, and 30 nmol or TCS OX2 29 as an orexin-2 receptor (OX2r) antagonist at the same doses were microinjected into the CA1 region in rats. Five minutes later, rats were exposed to restraint stress (RS) for 3 h, and pain-related behaviors were monitored in 5-min blocks for the 60-min test period in the formalin test. Results showed that applying RS for 3 h reduced pain responses in the early and late phases of the formalin test. The main findings showed that intra-CA1 injection of orexin receptor antagonists reduced the antinociception caused by stress in both phases of the formalin test. In addition, the contribution of OX2r in mediating the antinociceptive effect of stress was more prominent than that of OX1r in the early phase of the formalin test. However, in the late phase, both receptors worked similarly. Accordingly, the orexin system and its two receptors in the CA1 region of the hippocampus regulate SIA response to this animal model of pain in formalin test.
PURPOSE: To obtain the subject new and effective suppressant for melagenosis, containing an extracted essence of Citri Leiocarpae Exocarpium as an active ingredient and capable of providing a cosmetic having excellent beautifying and whitening effects and preventing and therapeutic effects on dermal stains and ephelides due to sunburn, etc., and high safety. CONSTITUTION: This suppressant for melanogenesis contains an extracted essence of Citri leiocarpae Exocarpium as an active ingredient. An ethanol extract, etc., obtained by adding, e.g. 1l ethanol to 30-150g dried and then pulverized Citri Leiocarpae Exocarpium, heating the mixture at 70 deg.C, then digesting the mixture for 3hr while refluxing can be used as the extracted essence. When the objective suppressant is used in the form of a dermal preparation for external use, the amount of the blended extracted essence of the Citri Leiocarpae Exocarpium is preferably 0.005-0.1wt.% expressed in terms of the dried weight of the extracted essence based on the total weight of the dermal preparation for external use.  Furthermore, usually used suppressants for the melanogenesis, ultraviolet light absorbers, ultraviolet light scattering agents, antinflammatory agents, etc., may be blended in preparing the skin preparation for external use.
The invention discloses a traditional Chinese medicine for treating tetanus. The traditional Chinese medicine is prepared from the following raw materials: radix saposhnikoviae, herba schizonepetae, periostracum cicadae, rhizoma typhonii, ramulus cinnamomi, radix paeoniae alba, radix astragali, rhizoma atractylodis macrocephalae, scorpion, stiff silkworm, earthworm, centipede, radix salviae miltiorrhizae, caulis spatholobi, rhizoma pinelliae, rhizoma arisaematis, radix clematidis and pangolin scales at a ratio of 5:1:1:1:1:1:1:1:1:1:1:1:1:1:2:5:1:2. The dry raw materials are carefully selected and ground into fine powder which is then mixed according to the ratio and packaged in bags (28g for each bag). Compared with injection of rabies vaccine or serum immunoglobulin, the traditional Chinese medicine disclosed by the invention has the advantages of convenience, practicability, lower treatment cost and the like. Meanwhile, a patient inoculated with rabies vaccine necessarily avoids spicy food and wine, but after the traditional Chinese medicine is externally applied, the patient does not need to avoid anything. Moreover, the patient generates antibody 10 days after the injection of the rabies vaccine, and the rabies vaccine cannot be injected 24 hours later since the patient is bitten, but the traditional Chinese medicine disclosed by the invention can be used anytime.